Chest
CorrespondenceFEV1/FVC Fixed Ratio Again!
Section snippets
To the Editor
I read with great interest in a recent issue of CHEST (November 2010) the Point/Counterpoint Editorials1, 2 on the FEV1/FVC fixed ratio of <0.7 to detect airflow obstruction and limitation. Although I was satisfied with the pro arguments of Drs Celli and Halbert,1 I found no real novel evidence on the con side compared with a similar debate I had on the same issue a few years ago.3, 4, 5 I still do not understand why Drs Enright and Brusasco2 criticized only the GOLD (Global Initiative for
References (18)
- et al.
Point: should we abandon FEV1/FVC < 0.70 to detect airway obstruction? No
Chest
(2010) - et al.
Counterpoint: should we abandon FEV1/FVC < 0.70 to detect airway obstruction? Yes
Chest
(2010) - et al.
The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: the Lung Health Study
Chest
(2003) - et al.
Beclomethasone/formoterol in the management of COPD: a randomised controlled trial
Respir Med
(2010) - et al.
Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial
Lancet
(2005) - et al.
COPD guidelines: the important thing is not to stop questioning
Am J Respir Crit Care Med
(2007) Are GOLDen slumbers drug induced?
Am J Respir Crit Care Med
(2008)- et al.
Time to wake up!
Am J Respir Crit Care Med
(2008) - et al.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary
Am J Respir Crit Care Med
(2007)
Cited by (7)
Diagnosis of Chronic Obstructive Pulmonary Disease, simpler is better Complexity and simplicity
2013, European Journal of Internal MedicineSpirometric inclusion criteria of COPD patients in randomized clinical trials
2012, Respiratory MedicineAsthma in the older adult: Presentation, considerations and clinical management
2015, Expert Review of Clinical ImmunologyFEV1/FVC as a fixed cut-off is an accurate and reliable parameter for functional diagnosis of bronchial obstruction in COPD: PRO
2012, Rassegna di Patologia dell'Apparato RespiratorioClinical highlights from the 2011 ERS Congress in Amsterdam
2012, European Respiratory Journal
Financial/nonfinancial disclosures: The author has reported to CHEST the following conflicts of interest: Dr Fabbri has served as a consultant to AstraZeneca, Boehringer-Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Medestea, Merck Sharp & Dohme, Nycomed, and Sigma Tau; he has been paid lecture fees by AstraZeneca, Boehringer-Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Nycomed, and Pfizer Inc; and he has received grant support from Almirall, AstraZeneca, Boehringer-Ingelheim, Menarini, Schering Plough, Chiesi Farmaceutici, Chiesi Foundation, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Nycomed, Pfizer Inc, Italian Ministry of Health, and Italian Ministry for University and Research.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).